InMed Pharmaceuticals Inc. (INM) Tops Q1 EPS by 390c

InMed Pharmaceuticals Inc. (NASDAQ: INM) reported Q1 EPS of ($0.60), $3.90 better than the analyst estimate of ($4.50). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $700 thousand.

For earnings history and earnings-related data on InMed Pharmaceuticals Inc. (INM) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Is Treasury selloff a major issue for stock market bulls?
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c